Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Sangamo Therapeutics, Inc.”

106 pharma patents match "Sangamo Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 106
Index total 30,257
Page 5 / 5

Quick answer

This filtered view shows 106 pharmaceutical patents matching "Sangamo Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

106 results for “Sangamo Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 9877988

    Method of treating lysosomal storage diseases using nucleases and a transgene

    Sangamo Therapeutics, Inc. · Granted Jan 30, 2018 · Expires Jan 25, 2038

    granted
  2. US 9834787

    Targeted integration into stem cells

    Sangamo Therapeutics, Inc. · Granted Dec 5, 2017 · Expires Nov 30, 2037

    granted
  3. US 9833479

    Gene correction of SCID-related genes in hematopoietic stem and progenitor cells

    Sangamo Therapeutics, Inc. · Granted Dec 5, 2017 · Expires Nov 30, 2037

    granted
  4. US 9816074

    Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells

    Sangamo Therapeutics, Inc. · Granted Nov 14, 2017 · Expires Nov 9, 2037

    granted
  5. US 9783827

    DNA-binding proteins and uses thereof

    Sangamo Therapeutics, Inc. · Granted Oct 10, 2017 · Expires Oct 5, 2037

    granted
  6. US 9782437

    Methods and compositions for targeted cleavage and recombination

    Sangamo Therapeutics, Inc. · Granted Oct 10, 2017 · Expires Oct 5, 2037

    granted
  7. US 9777281

    Methods and compositions for regulation of transgene expression

    Sangamo Therapeutics, Inc. · Granted Oct 3, 2017 · Expires Sep 28, 2037

    granted
  8. US 9771403

    Methods and compositions for treating hemophilia

    Sangamo Therapeutics, Inc. · Granted Sep 26, 2017 · Expires Sep 21, 2037

    granted
  9. US 9757420

    Gene editing for HIV gene therapy

    Sangamo Therapeutics, Inc. · Granted Sep 12, 2017 · Expires Sep 7, 2037

    granted
  10. US 9717759

    Modification of CXCR4 using engineered zinc finger proteins

    Sangamo Therapeutics, Inc. · Granted Aug 1, 2017 · Expires Jul 27, 2037

    granted